etomoxir has been researched along with gsk0660 in 1 studies
| Studies (etomoxir) | Trials (etomoxir) | Recent Studies (post-2010) (etomoxir) | Studies (gsk0660) | Trials (gsk0660) | Recent Studies (post-2010) (gsk0660) |
|---|---|---|---|---|---|
| 260 | 8 | 93 | 55 | 0 | 45 |
| Protein | Taxonomy | etomoxir (IC50) | gsk0660 (IC50) |
|---|---|---|---|
| Peroxisome proliferator-activated receptor delta | Mus musculus (house mouse) | 0.048 | |
| Peroxisome proliferator-activated receptor delta | Homo sapiens (human) | 0.2099 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Guardia, D; Barroso, E; Coll, T; Gómez-Foix, AM; Laguna, JC; Palomer, X; Vázquez-Carrera, M | 1 |
1 other study(ies) available for etomoxir and gsk0660
| Article | Year |
|---|---|
Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.
Topics: Analysis of Variance; Animals; Blotting, Western; Carnitine O-Palmitoyltransferase; Cell Line; Cell Nucleus; Electrophoretic Mobility Shift Assay; Epoxy Compounds; Fatty Acids; Humans; Insulin Resistance; Interleukin-6; Mice; Muscle, Skeletal; NF-kappa B; PPAR delta; Protein Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfones; Thiazoles; Thiophenes | 2010 |